🏛️ Verified NIH Record • Updated 2026-06-02
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes (NCT05791201)
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Vertex Pharmaceuticals Incorporated
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Who can join: Review the eligibility criteria below.
Location: UHealth Diabetes Research Institute — Miami, Florida
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- UHealth Diabetes Research Institute — Miami, Florida
- University of Chicago — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center Montefiore — Pittsburgh, Pennsylvania
- University of Wisconsin — Madison, Wisconsin
- University of Alberta, Edmonton — Edmonton,
- Montreal Clinical Research Institute — Montreal,
- Toronto General Hospital (TGH) — Toronto,
- Vancouver General Hospital — Vancouver,
- Dresden Center for Islet Transplantation — Dresden,
- IRCCS Ospedale San Raffaele — Milan,
- Leiden University — Leiden,
- Hopiteaux Universitaires de Geneve — Geneva,
- Churchill Hospital — Headington,
- Royal Victoria Infirmary — Newcastle upon Tyne,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 1 Diabetes
- A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) — Hershey, Pennsylvania
- Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families — Jacksonville, Florida
- Diabetes Inspired Culinary Education (DICE): Culinary Medicine Intervention for At-Risk Youth With Type 1 Diabetes — Cleveland, Ohio
- GO TEAM: Glucose Optimization Through Technology Assisted Management — Cleveland, Ohio
- REAL-Fam Feasibility Study for Youth Diabetes Management — Chapel Hill, North Carolina
- Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes — New York, New York
Explore by condition: All Type 1 Diabetes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.